The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from

For full trial details, please see the original record at

Registration number
Ethics application status
Date submitted
Date registered
Date last updated

Titles & IDs
Public title
Healthy Volunteer Solid Oral Dose and Multiple Ascending Dose Evaluation of CTP-656
Scientific title
A Two-Part Phase 1 Healthy Volunteer Study: A Crossover Comparison of CTP-656 Solid Dose Formulation vs. Kalydeco® and a Double-Blind, Placebo-Controlled, Ascending Multiple Dose Evaluation of CTP-656
Secondary ID [1] 0 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Healthy 0 0
Condition category
Condition code

Study type
Description of intervention(s) / exposure
Treatment: Drugs - CTP-656
Treatment: Drugs - Placebo for CTP-656
Treatment: Drugs - Kalydeco

Experimental: CTP-656, 150 mg - Single Oral Dose

Active Comparator: Kalydeco, 150 mg - Single oral dose

Experimental: CTP-656, 75 mg or matching placebo - Subjects will be administered 75 mg CTP-656 for 7 days.

Experimental: CTP-656, 150 mg or matching placebo - Subjects will be administered 150 mg CTP-656 for 7 days.

Experimental: CTP-656, high dose or matching placebo - Subjects will be administered up to 300 mg CTP-656 for 7 days.

Treatment: Drugs: CTP-656

Treatment: Drugs: Placebo for CTP-656

Treatment: Drugs: Kalydeco

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Primary outcome [1] 0 0
Number of Participants with Adverse Events as a Measure of Safety and Tolerability - adverse events categorized by body system and MedDRA term
Timepoint [1] 0 0
7 days
Primary outcome [2] 0 0
Measure exposure of test articles using area under the concentration time curve (AUC)
Timepoint [2] 0 0
96 hours

Key inclusion criteria
- Healthy adults between 18 and 50 years of age, inclusive

- Body weight = 50 kg and BMI within the range of 18 to 30 kg/m2, inclusive, at
Minimum age
18 Years
Maximum age
50 Years
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
- History of clinically significant central nervous system (eg, seizures), cardiac,
pulmonary, metabolic, renal (including nephrolithiasis), hepatic, including history of
Gilbert's syndrome or gastrointestinal (GI) conditions

- PR interval = 220 msec or QRS duration = 120 msec or QTcF interval > 450 msec obtained
at screening visit or prior to the first dose of study drug

- Liver function tests greater than the upper limit of normal.

- Positive blood screen for human immunodeficiency virus (HIV antibody), hepatitis B
virus surface antigen, or hepatitis C virus antibody at screening

- Urinalysis positive for greater than trace blood, protein or glucose

- A positive screen for alcohol, drugs of abuse, or tobacco use.

- Inability to comply with food and beverage restrictions during study participation.

- Donation or blood collection or acute loss of blood prior to screening.

Study design
Purpose of the study
Basic Science
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Other design features
Phase 1
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
- Adelaide
Recruitment postcode(s) [1] 0 0
5000 - Adelaide

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Concert Pharmaceuticals

Ethics approval
Ethics application status

Brief summary
Two-part study to assess CTP-656 dosed as a solid oral dosage form versus Kalydeco and
multiple-ascending doses of CTP-656 dosed for 7 days.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 0 0
Lana Pilja
Address 0 0
Concert Pharmaceuticals, Inc.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications